Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditar

Investors interested in stocks from the Medical - Products sector have probably already heard of Phi

Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises t

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds rece

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the w

ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare T

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchis

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma

Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target,

Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the pri

Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE: HAE) during the sec

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65.

Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a sign

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other bi

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday'

Haemonetics anticipates CSL to transition a portion of its U.S. plasma collection centers to the Com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasm

Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's fo

Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6%

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus E

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 bill

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

Analysts upgraded HAE, VIK, and TXN, and raised price targets. Check out other analysts' views o

B of A Securities analyst Craig Bijou upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and rai

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price

FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consens

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innova

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the p

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an